Roche Says Gazyva Achieved 36.1% Complete Remission at Two Years
In the Phase III MAJESTY study, Gazyva/Gazyvaro achieved a 36.1% complete remission rate at two years, versus 5.7% with tacrolimus.
In the Phase III MAJESTY study, Gazyva/Gazyvaro achieved a 36.1% complete remission rate at two years, versus 5.7% with tacrolimus.